Medical device company LeMaitre Vascular (NASDAQ:LMAT) in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next ...

Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

Citizens JMP raised the firm’s price target on LeMaitre (LMAT) to $113 from $100 and keeps an Outperform rating on the shares. LeMaitre’s Q4 ...

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...

Barrington analyst Michael Petusky downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q4 report.

LeMaitre Vascular Inc (LMAT) reports robust sales growth and strategic global expansion, while navigating regulatory and ...

Truist Financial Corp increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 21.0% during the 4th quarter, according to its most recent disclosure with the SEC. The ...

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.

Learn more about whether LeMaitre Vascular, Inc. or Teleflex Incorporated is a better investment based on AAII's A+ Investor ...

For the current quarter ending in March, LeMaitre said it expects revenue in the range of $56.7 million to $58.7 million. The company expects full-year earnings to be $2.15 to $2.32 per share, with ...

On Friday, Oppenheimer analysts downgraded LeMaitre Vascular (NASDAQ:LMAT) stock rating from Outperform to Perform. The decision came after the company’s fourth-quarter earnings report ...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results ...